TriangleTRK-950 (NCT06038578)
TRK-950 trial for Gastric Adenocarcinoma (NCT06038578). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HER2-negative gastric or gastroesophageal-junction adenocarcinoma that is metastatic or unresectable, has progressed after qualifying treatment, and meets CAPRIN-1 staining requirements. Prior ramucirumab or paclitaxel is excluded.
The idea: add TRK-950, an antibody targeting CAPRIN-1 that may recruit immune cells to kill tumor cells. Randomized groups receive ramucirumab and paclitaxel alone or with either of two TRK-950 doses, all by infusion in four-week cycles. Researchers compare time without progression and safety.
This phase 2 study plans 146 patients. Toray sponsors fourteen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.